BioSpace News Archive

Alpha Tau Medical Ltd. announced today the successful closing of the previously announced business combination (the “Business Combination”).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the companies will host a business update conference call on Monday, March 28, 2022, at 4:30 PM EDT.

AnaptysBio, Inc. today reported operating results for the fourth quarter and year ended December 31, 2021 and provided pipeline updates.

Biofrontera Inc. announces the appointment of Kevin D. Weber to its Board of Directors, expanding Board membership to five Directors.

Debbie’s Dream Foundation: Curing Stomach Cancer hosted a successful 10th Annual Stomach Cancer Capitol Hill Advocacy Day on February 7 and 8, 2022.

ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce a poster showing strong correlation between ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at Cowen’s 42nd Annual Health Care Conference, which will be held virtually.

Singleron Biotechnologies announced the acquisition of Proteona Pte. Ltd., a Singapore-based precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers across the globe.

The global eClinical solutions market size is expected to reach over USD 16.36 billion by 2027 and is expanding growth at a CAGR 13.6% during the forecast period 2021 to 2027.